RU94027680A - Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы - Google Patents

Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы

Info

Publication number
RU94027680A
RU94027680A RU94027680/14A RU94027680A RU94027680A RU 94027680 A RU94027680 A RU 94027680A RU 94027680/14 A RU94027680/14 A RU 94027680/14A RU 94027680 A RU94027680 A RU 94027680A RU 94027680 A RU94027680 A RU 94027680A
Authority
RU
Russia
Prior art keywords
mass increase
parathyroid hormone
raloxifen
pharmaceutical composition
osseous
Prior art date
Application number
RU94027680/14A
Other languages
English (en)
Other versions
RU2155042C2 (ru
Inventor
Мэри Хок Джанет
Us]
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94027680A publication Critical patent/RU94027680A/ru
Application granted granted Critical
Publication of RU2155042C2 publication Critical patent/RU2155042C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение включает в себя способ увеличения костной массы у пациента путем ввода паращитовидного гормона и ралоксифена. Другим признаком изобретения является способ лечения заболевания кости путем ввода паращитовидного гормона и ралоксифена. Также изобретение относится к составу из паращитовидного гормона и ралоксифена для увеличения костной массы у пациента. Другим признаком изобретения является композиция из паращитовидного гормона и ралоксифена для печения заболевания кости у пациента.

Claims (1)

  1. Изобретение включает в себя способ увеличения костной массы у пациента путем ввода паращитовидного гормона и ралоксифена. Другим признаком изобретения является способ лечения заболевания кости путем ввода паращитовидного гормона и ралоксифена. Также изобретение относится к составу из паращитовидного гормона и ралоксифена для увеличения костной массы у пациента. Другим признаком изобретения является композиция из паращитовидного гормона и ралоксифена для печения заболевания кости у пациента.
RU94027680/14A 1993-07-22 1994-07-19 Паращитовидный гормон и ралоксифен для увеличения массы кости, фармацевтический состав и способ увеличения костной массы RU2155042C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9648093A 1993-07-22 1993-07-22
US08/096,480 1993-07-22

Publications (2)

Publication Number Publication Date
RU94027680A true RU94027680A (ru) 1996-11-10
RU2155042C2 RU2155042C2 (ru) 2000-08-27

Family

ID=22257534

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94027680/14A RU2155042C2 (ru) 1993-07-22 1994-07-19 Паращитовидный гормон и ралоксифен для увеличения массы кости, фармацевтический состав и способ увеличения костной массы

Country Status (30)

Country Link
US (1) US5510370A (ru)
EP (1) EP0635270B1 (ru)
JP (1) JPH0769920A (ru)
KR (1) KR100306852B1 (ru)
CN (1) CN1105577C (ru)
AT (1) ATE189959T1 (ru)
AU (1) AU686628B2 (ru)
BR (1) BR9402902A (ru)
CA (1) CA2128376A1 (ru)
CY (1) CY2192B1 (ru)
CZ (1) CZ289648B6 (ru)
DE (1) DE69423146T2 (ru)
DK (1) DK0635270T3 (ru)
ES (1) ES2142380T3 (ru)
GR (1) GR3033492T3 (ru)
HK (1) HK1013800A1 (ru)
HU (1) HU219382B (ru)
IL (1) IL110350A (ru)
MY (1) MY124311A (ru)
NO (1) NO942708L (ru)
NZ (2) NZ264027A (ru)
PE (1) PE14595A1 (ru)
PH (1) PH30686A (ru)
PL (1) PL304348A1 (ru)
PT (1) PT635270E (ru)
RU (1) RU2155042C2 (ru)
SI (1) SI0635270T1 (ru)
TW (1) TW303299B (ru)
YU (1) YU49170B (ru)
ZA (1) ZA945249B (ru)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5578613A (en) * 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5972383A (en) * 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5811120A (en) * 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5502074A (en) * 1994-08-22 1996-03-26 Eli Lilly And Company Benzothiophenes for bone healing and fracture repair
EP0804202A4 (en) * 1994-09-09 1999-01-13 Procter & Gamble Estrogens and parathyroid hormone for the treatment of osteoporosis
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
EP0724879A2 (en) * 1995-02-06 1996-08-07 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiopenes for inhibiting effects of IL-6
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
AU761274B2 (en) * 1996-01-29 2003-05-29 Schering Aktiengesellschaft Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
WO1999004808A1 (fr) * 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Medicaments dentaires contenant de la pth
EP1030658A1 (en) * 1997-10-14 2000-08-30 Eli Lilly And Company Method of building and maintaining bone
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
WO2000019823A1 (en) * 1998-10-07 2000-04-13 The Board Of Trustees Of The University Of Arkansas Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof
US6416737B1 (en) 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20040214889A1 (en) * 1999-07-31 2004-10-28 Smithkline Beecham Corporation Calcilytic compounds
EP1222465A1 (en) * 1999-09-20 2002-07-17 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
ATE314822T1 (de) * 2000-10-10 2006-02-15 Microchips Inc Mikrochip-reservoir-vorrichtungen mit drahtloser übertragung von energie und daten
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
CA2468719C (en) * 2001-11-29 2011-05-24 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
BR0311774A (pt) * 2002-06-13 2007-05-08 Wyeth Corp regimes de tratamento com bazedoxifeno
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
SG149081A1 (en) * 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
BRPI0509788A (pt) 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
AU2006208131A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
US7691105B2 (en) * 2005-09-26 2010-04-06 Depuy Spine, Inc. Tissue augmentation, stabilization and regeneration technique
US20070088436A1 (en) * 2005-09-29 2007-04-19 Matthew Parsons Methods and devices for stenting or tamping a fractured vertebral body
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20070168041A1 (en) * 2006-01-17 2007-07-19 Sudhakar Kadiyala Method and instruments for intervertebral disc augmentation through a pedicular approach
WO2009131553A2 (en) 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
JP2010523243A (ja) * 2007-04-13 2010-07-15 クロス・バイオサージェリー・アクチェンゲゼルシャフト 高分子組織シーラント
US8241294B2 (en) * 2007-12-19 2012-08-14 Depuy Spine, Inc. Instruments for expandable corpectomy spinal fusion cage
US8241363B2 (en) 2007-12-19 2012-08-14 Depuy Spine, Inc. Expandable corpectomy spinal fusion cage
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8876905B2 (en) * 2009-04-29 2014-11-04 DePuy Synthes Products, LLC Minimally invasive corpectomy cage and instrument
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
AU2011239935A1 (en) * 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
WO2015187994A1 (en) * 2014-06-04 2015-12-10 Cedars-Sinai Medical Center Method for non surgical repair of vertebral compression fractures
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
MY124311A (en) 2006-06-30
BR9402902A (pt) 1995-04-11
IL110350A (en) 2002-02-10
GR3033492T3 (en) 2000-09-29
ZA945249B (en) 1996-01-18
KR100306852B1 (ko) 2001-11-30
DK0635270T3 (da) 2000-06-05
PE14595A1 (es) 1995-06-01
PT635270E (pt) 2000-07-31
CZ173394A3 (en) 1995-04-12
NZ280040A (en) 1997-06-24
NO942708L (no) 1995-01-23
NO942708D0 (no) 1994-07-19
SI0635270T1 (en) 2000-08-31
ATE189959T1 (de) 2000-03-15
ES2142380T3 (es) 2000-04-16
CA2128376A1 (en) 1995-01-23
AU6757794A (en) 1995-02-02
HK1013800A1 (en) 1999-09-10
CN1105577C (zh) 2003-04-16
US5510370A (en) 1996-04-23
CY2192B1 (en) 2002-11-08
YU46794A (sh) 1997-03-07
KR950002785A (ko) 1995-02-16
NZ264027A (en) 1996-03-26
PL304348A1 (en) 1995-01-23
HU219382B (en) 2001-03-28
EP0635270A1 (en) 1995-01-25
YU49170B (sh) 2004-05-12
DE69423146D1 (de) 2000-04-06
RU2155042C2 (ru) 2000-08-27
TW303299B (ru) 1997-04-21
JPH0769920A (ja) 1995-03-14
PH30686A (en) 1997-09-16
HUT67945A (en) 1995-05-29
HU9402157D0 (en) 1994-09-28
EP0635270B1 (en) 2000-03-01
CZ289648B6 (cs) 2002-03-13
AU686628B2 (en) 1998-02-12
CN1105882A (zh) 1995-08-02
DE69423146T2 (de) 2000-09-21
IL110350A0 (en) 1994-10-21

Similar Documents

Publication Publication Date Title
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
RU92004521A (ru) Применение бисфосфонатов и экстракта паращитовидных желез для лечения остеопороза и набор для лечения
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
RU94031209A (ru) Применение бисфосфонатов и гормона околощитовидной железы для лечения остеопороза
DE69815122T2 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DZ1884A1 (fr) Formulations orales liquides d'alendronate.
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
RU95106821A (ru) Циклопептиды, способ их получения, фармацевтическая композиция и способ ее получения
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
ES2145902T3 (es) Aplicacion del riluzole en el tratamiento de las enfermedades mitocondriales.
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
KR890014124A (ko) Il-6 분자의 사용방법
NO980375L (no) Humant MP52 Arg protein
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
KR960003741A (ko) 조골세포 증식인자
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
UA19596A (ru) Способ лечения гипертонической болезни гирудорефлексотерапией
RU94016144A (ru) Средство для лечения больных болезнью рейтера
RU94020918A (ru) Способ лечения опсоменореи

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050720